Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

47.42 -1.03 (-2.13%)

Official Closing Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

99 100 Next >

Why Novo Nordisk Stock Is Sinking Today ↗

June 23, 2025

Via The Motley Fool

Topics Stocks Supply Chain

Stocks Rise, Oil Tumbles Despite Iran's Strikes On US Bases: What's Driving Markets Monday? ↗

June 23, 2025

Wall Street resilient as Iran fires missiles at U.S. bases in Qatar and Iraq, defying expectations in energy market. U.S. equities and gold up, bonds down.

Via Benzinga

Topics Bonds

Hims & Hers Stock Plunges As Novo Nordisk Ends Partnership Over Allegations Of Selling Knockoff Versions Of Wegovy ↗

June 23, 2025

Novo said that Hims & Hers failed to adhere to the law, which prohibits mass sales of compounded drugs. It alleged that the telehealth operator is promoting and selling illegitimate, knockoff versions...

Via Stocktwits

Topics Law Enforcement

Hims & Hers Health Stock Is Tumbling Monday: What's Happening? ↗

June 23, 2025

Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Monday after Novo Nordisk A/S (NYSE:NVO) terminated its collaboration with the company.

Via Benzinga

Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern ↗

June 23, 2025

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.

Via Benzinga

IBD 50's Hims Plummets After Novo Yanks Deal Over 'Deceptive' And 'Illegitimate' Wegovy Knockoffs ↗

June 23, 2025

Hims stock plummeted Monday after Novo Nordisk ended their collaboration over concerns about Hims' compounded semaglutide.

Via Investor's Business Daily

Dow Futures Edge Lower As Iran Moves To Block Strait Of Hormuz: Exxon, Chevron, Occidental, Tesla Among Stocks In Focus ↗

June 23, 2025

Via Stocktwits

Topics Stocks

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock with Reasonable Valuation ↗

June 23, 2025

NOVO-NORDISK (NYSE:NVO) offers strong growth, high profitability, and reasonable valuation, making it an attractive candidate for investors seeking affordable growth stocks.

Via Chartmill

Watch Out, Novo Nordisk & Eli Lilly: Chinese Biotech Steps Into the Ring To Take On Global Weight-Loss Leaders ↗

June 23, 2025

Sciwind Biosciences is expanding its global footprint with licensing deals and early talks for overseas development, as it eyes a double-digit market share in China's fast-growing obesity drug sector.

Via Stocktwits

Novo Nordisk Gains Ground In Obesity Race As Amycretin, Wegovy Show Significant Weight Loss ↗

June 22, 2025

The company is advancing amycretin to Phase 3 and pursuing regulatory approval for a higher Wegovy dose.

Via Stocktwits

5 Health Care Stocks With Whale Alerts In Today's Session ↗

June 20, 2025

Via Benzinga

McDonald’s Is Down, But Long-Term Investors Can Still Take a Bite

June 20, 2025

Analysts are downgrading McDonald's and the stock may have further to fall, but as a long-term opportunity, it may be getting to a point of offering real value

Via MarketBeat

How Do Investors Really Feel About Novo Nordisk? ↗

June 19, 2025

Via Benzinga

How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl ↗

June 19, 2025

This dark horse candidate has emerged to take significant share in the weight-loss drugs space.

Via Investor's Business Daily

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - A Strong Candidate for Value Investors ↗

June 19, 2025

NOVO-NORDISK A/S (NYSE:NVO) is a strong value stock with high profitability, solid growth, and an attractive valuation, making it a candidate for long-term investors.

Via Chartmill

Why Scholar Rock Shares Are Soaring Today ↗

June 18, 2025

Via The Motley Fool

Topics Stocks

US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies ↗

June 18, 2025

The judge said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list, Reuters reported.

Via Stocktwits

Topics Lawsuit

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study ↗

June 18, 2025

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial.

Via Benzinga

Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy? ↗

June 18, 2025

Via The Motley Fool

Topics Artificial Intelligence

Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities

June 17, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TNDM),(NYSE:NVO),(NASDAQ:PODD),(NYSE:MDT) EQNX::TICKER_END

Via FinancialNewsMedia

Why Novo Nordisk Stock Sank by Nearly 4% Today ↗

June 16, 2025

Via The Motley Fool

Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities

June 17, 2025

From FN Media Group LLC

Via GlobeNewswire

Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor ↗

June 16, 2025

A simple oversight could end up costing Danish pharma giant Novo Nordisk A/S (NYSE: NVO) billions in potential losses on its blockbuster weight-loss and diabetes drug, Ozempic.

Via Benzinga

Topics Intellectual Property

3 Growth Stocks You Can Buy Right Now Without Any Hesitation ↗

June 16, 2025

Via The Motley Fool

1 Growth Stock Down 9% to Buy Right Now ↗

June 14, 2025

Via The Motley Fool

Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company ↗

June 13, 2025

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions.

Via Benzinga

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today ↗

June 13, 2025

Via Benzinga

Why Novo Nordisk Stock Pumped Higher on Thursday ↗

June 12, 2025

Via The Motley Fool

Novo Nordisk’s Plan To Start Late-Stage Trial Of Investigational Obesity Drug Amycretin In 2026 Gets Retail Talking ↗

June 12, 2025

The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from regulators following mid-stage studies.

Via Stocktwits

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 12, 2025

Via Benzinga

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

All News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today